New Risk-Adapted drug combo aims to outsmart lymphoma
NCT ID NCT06793189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a personalized approach to treating marginal zone lymphoma, a slow-growing blood cancer. Researchers assign patients to different drug combinations based on their risk score, using targeted therapies like obinutuzumab, orelabrutinib, and lenalidomide. The goal is to improve how long the cancer stays away while keeping side effects manageable. About 145 newly diagnosed patients who need systemic treatment will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
obinutuzumab, orelabrutinib, and lenalidomide
What this could lead to
If successful, this could provide a more personalized, effective treatment for marginal zone lymphoma, potentially improving long-term disease control and reducing side effects.
What could go wrong
This is a Phase 2 trial with only 145 participants, so results may not apply to everyone. The drugs can cause serious side effects like infections, low blood counts, and organ toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
Contact Email: •••••@•••••
-
Peking University Third Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
-
Shanghai Ruijin Hospital
RECRUITINGShanghai, China, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••